HIT Consultant June 10, 2024
What You Should Know:
– ALZpath, a leader in Alzheimer’s disease diagnostics, announced a licensing agreement with Roche for their innovative pTau217 antibody. This paves the way for a blood test to diagnose Alzheimer’s disease using Roche’s widely used Elecsys® platform.
– The Roche pTau217 test has already received Breakthrough Device designation from the FDA and will be commercialized as part of a collaboration between Roche and Eli Lilly.
pTau217: A Game Changer in Alzheimer’s Detection
pTau217 is a protein biomarker crucial for detecting and tracking Alzheimer’s progression in a simple blood test. This offers a significant advantage over traditional methods like PET scans or cerebrospinal fluid (CSF) testing, which are expensive, invasive, and less accessible.
Transforming Alzheimer’s...
Today's Sponsors
Today's Sponsor